Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ADU S100

Drug Profile

ADU S100

Alternative Names: ADU-S100; MIW 815

Latest Information Update: 25 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aduro BioTech
  • Developer Aduro BioTech; Novartis
  • Class Antineoplastics; Nucleotides; Small molecules
  • Mechanism of Action Immunostimulants; MPYS protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Head and neck cancer
  • Phase I Lymphoma; Solid tumours
  • No development reported Malignant melanoma

Most Recent Events

  • 01 Jun 2019 Phase-II clinical trials in Head and neck cancer (Combination therapy, First-line therapy, Metastatic disease, Recurrent) in USA (Intratumoural) (NCT03937141)
  • 31 May 2019 Interim efficacy, pharmacokinetics and adverse events data from a phase Ib trial in Solid tumors and Lymphoma presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
  • 03 May 2019 Aduro BioTech plans a phase II trial for Head and neck cancer (Combination therapy, Metastatic disease, Recurrent) (Intratumoural) in 2H of 2019 (NCT03937141)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top